Target intelligence / Profile preview

Technetium Tc 99m albumin aggregated (MAA)

Target
MAA
Molecular classification
Protein aggregate, Radiopharmaceutical carrier, Other
01

Overview

Macro-aggregated albumin (MAA) carrier particles are aggregates of denatured human serum albumin used as a diagnostic radiopharmaceutical vehicle [1]. When labeled with Technetium-99m (Tc-99m), they are primarily employed in lung perfusion scintigraphy to visualize pulmonary blood flow and identify defects associated with pulmonary embolism [1][3]. The particles, ranging in size from 10 to 90 micrometers, function through the mechanism of temporary capillary blockade, where they are physically trapped in the precapillary arterioles of the lungs [1][2]. In addition to pulmonary imaging, MAA is used in interventional radiology to assess the lung shunt fraction before selective internal radiation therapy (SIRT) for liver malignancies, ensuring that subsequent therapeutic microspheres do not cause excessive radiation pneumonitis [4]. As a physical diagnostic agent, MAA does not interact with specific biological receptors or enzymes and is therefore classified as a carrier rather than a therapeutic target [1][3].

Other names
Tc-99m MAAMacroaggregated albuminHuman albumin macroaggregatesTechnetium Tc-99m macroaggregated albumin
02

Mechanism of action

Mechanical entrapment in pulmonary precapillary arterioles (capillary blockade) based on particle size (10-90 micrometers).

03

Biological functions

Pulmonary capillary blockadeLung perfusionOther
04

Disease associations

Pulmonary embolismHepatocellular carcinomaCardiovascular diseaseOther
05

Safety considerations

Severe pulmonary hypertensionHypersensitivity to human serum albuminRight-to-left shunt (risk of systemic/cerebral embolization)
06

Interacting drugs

Technetium-99m
07

Biomarkers

Lung shunt fractionPerfusion defect

Beyond the preview

Go deeper on Technetium Tc 99m albumin aggregated (MAA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Technetium Tc 99m albumin aggregated (MAA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call